Lenalidomide Teva (Lenalidomide)

Lenalidomide binds to the cereblon protein within the CRL4‑E3 ubiquitin ligase complex, causing selective degradation of the transcription factors Ikaros and Aiolos. This action suppresses malignant plasma‑cell growth, enhances immune‑mediated tumor cell killing, and blocks new blood‑vessel formation that supports cancer.

The specific dose of Lenalidomide Teva is determined by the treating physician based on the patient’s diagnosis, disease stage, renal function and other clinical factors. Prescribers follow approved labeling and clinical guidelines to set the appropriate regimen.

Lenalidomide is classified as a teratogenic drug and is contraindicated during pregnancy. Women of child‑bearing potential must use effective contraception before, during and after treatment. Safety during breastfeeding has not been established, so nursing is generally discouraged while on therapy.

To place an order, submit an enquiry on the Lenalidomide Teva product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Lenalidomide and thalidomide belong to the same immunomodulatory class, but lenalidomide is generally more potent, has a more favorable safety profile, and is less likely to cause peripheral neuropathy. Both target cereblon, yet lenalidomide’s broader anti‑angiogenic and immune‑activating effects make it a preferred option in many treatment protocols.

Lenalidomide Teva tablets should be stored at room temperature, below 25 °C, in the original blister pack or container. Protect the product from excess moisture, heat and direct sunlight. Keep out of reach of children and do not use if the packaging is damaged.

Lenalidomide Teva is taken orally, usually once daily, with or without food, as directed by the prescribing clinician. The tablets should be swallowed whole with water and not crushed or chewed unless specifically instructed. Treatment cycles and duration are defined by the treating physician.

The most serious risks include severe neutropenia or leukopenia that can predispose to infection, thromboembolic events such as deep‑vein thrombosis or pulmonary embolism, and the potential for second primary cancers. Patients should be monitored regularly for blood‑count changes and signs of clotting.

Lenalidomide Teva should not be used by individuals who are pregnant, have uncontrolled infections, or have a known hypersensitivity to lenalidomide or any of its excipients. Caution is also advised for patients with severe renal or hepatic impairment, and the drug is avoided in those receiving live vaccines.